English, Article edition: Economic Analysis of Fluconazole versus Amphotericin B for the Treatment of Candidemia in Non-Neutropenic Patients George Dranitsaris; Peter Phillips; Coleman Rotstein; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/95124
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Analysis of Fluconazole versus Amphotericin B for the Treatment of Candidemia in Non-Neutropenic Patients
Author
  • George Dranitsaris
  • Peter Phillips
  • Coleman Rotstein
  • Anitasha Puodziunas
  • Steve Shafran
  • Gary Garber
  • Fiona Smaill
  • Irving Salit
  • Mark Miller
  • Kurt Williams
  • John Conly
  • Joel Singer
  • Steve Ioannou
Physical Description
  • article
Notes
  • Fluconazole (FLU) is an alternative to amphotericin B (AMB) for the treatment of candidemia in non-neutropenic patients. This agent has similar clinical efficacy but significantly reduced adverse effects compared with AMB. Using the database from a Canadian randomised multicentre comparative trial of FLU versus AMB in the treatment of non-neutropenic patients with candidemia, an economic analysis of antifungal therapy was conducted from a Canadian hospital perspective. Patient records were examined for information containing hospital resource consumption. This included the costs for primary intravenous therapy with either AMB or FLU, laboratory tests, patient clinical monitoring and adverse effects management. The robustness of the baseline results were then tested by a comprehensive sensitivity analysis. The mean duration of therapy in the AMB and FLU arms was 17.1 and 23.7 days, respectively (p < 0.001). Assuming that all of the FLU was administered intravenously, the outcomes of the baseline economic analysis revealed that the treatment cost for patients randomised to receive FLU was approximately 50% higher than that for patients treated with AMB [AMB: $Can2370 vs FLU: $Can3578; p =​ 0.001 ($Can =​ Canadian dollars)]. In the sensitivity analysis, substitution to oral FLU after 7 days of intravenous therapy produced economic differences that were no longer statistically significant (AMB: $Can2370 vs FLU: $Can2705; p =​ 0.10). These results suggest that the FLU administration regimen used in the Canadian randomised trial for the treatment of candidemia in non-neutropenic patients may result in increased hospital costs compared with AMB. However, comparable expenditures could be realised if FLU is administered intravenously for the first 7 days and then orally in patients whose condition allows for reliable oral therapy.
  • Fluconazole, Amphotericin-B, Candidiasis, Cost-analysis, Pharmacoeconomics, Antifungals
  • RePEc:wkh:phecon:v:13:y:1998:i:5:p:509-518
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment